Tackling Medicine's Graveyard: Can a €14M Dutch Biotech Breakthrough Finally Neutralize Sepsis?

GELEEN, NETHERLANDS – September 17, 2026 – In the high-stakes world of critical care medicine, sepsis is widely known as the "graveyard of drug development." Over the past four decades, more than a hundred late-stage clinical trials have failed, costing the biopharmaceutical industry billions of dollars and leaving intensive care units with little more than supportive therapies to fight a condition that claims 11 million lives globally each year.

Today, Dutch clinical-stage biotech Matisse Pharmaceuticals announced the completion of a €14 million Series A financing round aimed at rewriting this grim narrative. Backed by a syndicate of regional public-private funds including Brightlands Venture Partners and LIOF, alongside private investors and corporate management, the capital will fund a critical Phase 2 clinical trial for the company's lead candidate, isupartob sodium.

Rather than targeting the underlying infection or chasing the complex web of inflammatory cytokines, Matisse is taking a radically different, upstream approach: neutralizing the toxic extracellular histones that physically destroy blood vessels and drive the cascade of multiorgan failure. As the company advances into mid-stage trials, the biotech industry is watching closely to see if a biophysical "sponge" can succeed where decades of traditional pharmacology have failed.

The Sepsis Graveyard: Why Past Therapeutics Failed

To understand the significance of Matisse's clinical milestone, one must first understand the historical wreckage of sepsis therapeutics. Sepsis is not merely a severe infection; it is a dysregulated host response. When the immune system detects an invading pathogen, it can overreact, triggering a systemic inflammatory cascade that damages the body's own tissues and organs.

Historically, pharmaceutical companies attempted to intervene by blocking single inflammatory signaling molecules. Monoclonal antibodies targeting TNF-alpha or IL-1 failed repeatedly in Phase 3 trials. Because the immune system's cytokine network is highly redundant, blocking one pathway simply allowed others to take over. Worse, dampening the host's immune defense often exacerbated the underlying infection.

Other high-profile failures targeted specific pathogen receptors or clotting mechanisms. Eisai's Eritoran, which blocked the TLR4 endotoxin receptor, failed in 2011 because it was useless against Gram-positive bacteria, viruses, and fungi. Eli Lilly's Xigris (drotrecogin alfa), once the only approved sepsis drug, was pulled from the market in 2011 after follow-up studies showed no survival benefit and a dangerous increase in severe internal bleeding.

"The industry learned the hard way that you cannot treat sepsis by paralyzing the immune system or introducing systemic anticoagulants that cause patients to hemorrhage," noted one European life sciences venture analyst. "The holy grail is finding a target that acts downstream of the initial infection but upstream of irreversible organ collapse, without compromising blood clotting."

A Biophysical Sponge: The Science of Isupartob Sodium

Matisse Pharmaceuticals believes it has found that target in extracellular histones. When immune cells (like neutrophils) and other tissues die during a severe infection, they spill their structural proteins—histones—into the bloodstream. While safely confined within a cell's nucleus under normal conditions, free-floating histones are highly toxic. They act as aggressive damage-associated molecular patterns (DAMPs), binding directly to negatively charged endothelial membranes, punching holes in blood vessels, and causing microvascular collapse.

Isupartob sodium, recently granted the novel WHO stem "-partob" to denote its unique class, was engineered to intercept this process. Originating from foundational research at Maastricht University, the drug is a highly purified, fractionated variant of heparin. However, through a proprietary manufacturing process, Matisse has stripped away the specific pentasaccharide sequence responsible for heparin's blood-thinning properties.

What remains is a negatively charged biophysical "sponge." When administered intravenously, isupartob sodium electrostatically binds to the positively charged cytotoxic histones, neutralizing them before they can shred the vascular lining. Because it is pathogen-agnostic, the therapy could theoretically be deployed regardless of whether the sepsis was triggered by a bacterial pneumonia, a ruptured appendix, or a severe viral infection.

Early clinical data has been highly encouraging. In a Phase 1/2a trial involving critically ill ICU patients, a 6-hour continuous infusion of the drug proved safe, with 70% of treated patients demonstrating a measurable decrease in their Sequential Organ Failure Assessment (SOFA) scores within 72 hours. A subsequent trial in healthy volunteers confirmed that a 120-hour continuous infusion maintained predictable pharmacokinetics without inducing thrombocytopenia or dangerous bleeding.

The Pediatric Crisis and a $62 Billion Economic Toll

The urgency to validate isupartob sodium extends far beyond the scientific desire to conquer a difficult disease. Sepsis represents a staggering global health crisis, affecting roughly 49 million individuals annually.

Perhaps the most overlooked tragedy of the sepsis epidemic is its impact on children. Approximately 40% of all global sepsis cases occur in children under the age of five. Pediatric sepsis progresses with terrifying speed; surges of cytotoxic histones can damage alveolar and renal tissues within hours, driving severe acute respiratory distress syndrome (ARDS) and claiming the lives of nearly 3 million young children every year.

Economically, the burden is equally catastrophic. In the United States alone, sepsis is the single most expensive hospital condition, consuming over $62 billion annually in inpatient healthcare costs. Survivors frequently endure Post-Sepsis Syndrome, a debilitating mix of physical, cognitive, and psychological impairments that drive high rates of hospital readmission.

Despite this massive unmet need, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) currently have zero approved targeted therapies for the core dysregulated host response in sepsis. The recent FDA Investigational New Drug (IND) clearance and Fast Track Designation for isupartob sodium underscore the regulatory desperation for a viable intervention.

Regional Capital Driving Global Milestones

Executing a critical care clinical trial is notoriously complex and expensive. The €14 million Series A, structured as a company-led syndicate, represents a classic European capital-efficiency model.

Intensive care trials require continuous bedside drug administration, extensive biomarker sampling, and rigorous monitoring, often pushing the cost per patient to between $40,000 and $70,000. Industry benchmarks suggest that €14 million is a tightly calibrated budget for a multicenter Phase 2 dose-finding study. However, the funding is strategically designed to carry Matisse to a binary proof-of-concept inflection point: generating definitive data on safety, SOFA score improvements, and 28-day mortality.

"This financing represents an important milestone for Matisse," said Marcel Jacobs, Chief Executive Officer of Matisse Pharmaceuticals. "We are grateful for the continued commitment of our existing shareholders and are pleased to welcome new investors who share our long-term vision. Their support enables us to focus on what matters most: Successfully completing our Phase 2 clinical trial in sepsis patients and generating the clinical data needed to unlock the next stage of the company's development."

By leveraging the regional manufacturing infrastructure of the Brightlands Chemelot Campus and the foundational IP from Maastricht University, Matisse has managed to advance a highly scalable, fractionated therapeutic without the exorbitant overhead typical of recombinant biologics. If the Phase 2 trial validates the histone-neutralizing mechanism, Matisse will be positioned not only to seek lucrative pharmaceutical partnerships for late-stage registrational trials but to fundamentally alter the paradigm of critical care medicine.